Precigen (PGEN) News Today

Precigen, Inc. (NASDAQ: PGEN) shares have increased as investors respond to strong second-quarter results, improving earnings expectations, and bullish analyst coverage. The stock is trading near its 12-month high after recently moving well above its 50-day and 200-day moving averages.

• Positive Sentiment: Strong earnings and commercial momentum: Precigen reported second-quarter 2026 revenue of approximately $55 million, far exceeding analyst expectations, and earnings of $0.05 per share versus the expected $0.01 loss. Revenue was driven largely by PAPZIMEOS, whose sales reportedly doubled sequentially to $53.1 million. The company also achieved quarterly profitability, supporting the view that its commercial business is scaling rapidly. Precigen Q2 2026 Earnings Call Highlights
• Positive Sentiment: More favorable analyst outlook: HC Wainwright maintained a Buy rating and an $18 price target while raising its Q3 2026 EPS forecast to $0.05 from $0.01 and its full-year 2026 forecast to $0.14 from $0.02. The firm also lifted its FY2027 estimate to $0.44 from $0.34, reflecting expectations for continued profitability and growth. HC Wainwright Precigen Estimates
• Positive Sentiment: Additional bullish ratings: Zacks Research upgraded Precigen from “Hold” to “Strong Buy.” Separately, an investment analysis cited PAPZIMEOS’ FDA approval for recurrent respiratory papillomatosis, seven years of U.S. market exclusivity, possible European approval, and advancement of the PRGN-2009 program as potential drivers of future revenue. Zacks Research
• Neutral Sentiment: HC Wainwright’s projections imply a sharp earnings ramp, reaching $0.71 EPS in FY2028 and $1.49 EPS in FY2030. However, the firm made a small reduction to its FY2028 estimate, from $0.72 to $0.71, indicating that longer-term forecasts remain subject to execution risk.